BioNTech Acquires Biotheus to Enhance Cancer Therapies
Company Announcements

BioNTech Acquires Biotheus to Enhance Cancer Therapies

BioNTech SE (BNTX) has released an update.

BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its oncology strategy by securing global rights to an investigational bispecific antibody, BNT327/PM8002. This acquisition is expected to enhance BioNTech’s capabilities in developing next-generation cancer therapies, potentially setting a new standard of care for solid tumors. The transaction, which includes up to $150 million in milestone payments, is anticipated to close in the first quarter of 2025.

For further insights into BNTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyBioNTech to acquire Biotheus for upfront consideration of $800M
TheFlyBioNTech upgraded to Buy from Neutral at Goldman Sachs
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App